Aviva PLC Krystal Biotech, Inc. Transaction History

Aviva PLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 10, 2021	SELL	$62.14 - $81.82 $1.07 Million - $1.41 Million	-17,198 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$59.42 - $85.46 $706,860 - $1.02 Million	-11,896 Reduced 40.89%	17,198 $1.33 Million
Q4 2020 Feb 10, 2021	SELL	$40.64 - $61.38 $958,453 - $1.45 Million	-23,584 Reduced 44.77%	29,094 $1.75 Million
Q3 2020 Nov 12, 2020	SELL	$37.76 - $48.49 $98,968 - $127,092	-2,621 Reduced 4.74%	52,678 $2.27 Million
Q2 2020 Aug 13, 2020	SELL	$37.03 - $60.0 $1.39 Million - $2.26 Million	-37,644 Reduced 40.5%	55,299 $2.29 Million
Q1 2020 May 14, 2020	BUY	$35.02 - $65.64 $3.25 Million - $6.1 Million	92,943 New	92,943 $4.02 Million

307

24.4M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $3.97B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Aviva PLC, based on Form 13F filings with the SEC.

Stay updated on Aviva PLC with notifications on news.